Abstract Details

Title Does Aspirin Use Alter Seizure Collections during Elective Adult Inpatient Video EEG Monitoring?

Topic Epilepsy

Presentation(s) IN9 - (-)

Poster/Presentation
Number 003

Objective

Background Epilepsy incidence increases after age 60, perhaps due to inflammation and/or ischemia. The anti-inflammatory and anti-platelet medication aspirin may help decrease seizure frequencies in animal models of epilepsy, but has not been studied in adults with epilepsy. We examine if aspirin use alters seizure generation by retrospectively comparing collected seizure numbers from adult partial epilepsy patients on and off aspirin therapies who underwent VEEG.

Design/Methods 904 adult patient records were screened for aspirin use. Inclusion criteria: routine admissions, exclusively partial epilepsy or psychogenic nonepileptic events, age ? 40. Two arms were created: those with partial epilepsy, and those with psychogenic nonepileptic events (PNES). PNES patients were used to look at monitoring biases or disease specific effects. Each arm had controls- aspirin-free patients matched by diagnosis, age, sex. Outcomes included days monitored, # of seizures captured, total seizures on day 2. Aspirin doses were correlated with those outcomes.

Results Adults with partial epilepsy on aspirin (n=24) had fewer seizures captured on day 2 of monitoring (mean=0.71), than partial epilepsy controls (n=24) not on aspirin (mean=1.96, p=0.05). Days monitored and events captured were lower in the aspirin arm, those findings were not significant. Aspirin dose inversely correlated with fewer seizures on day 2 (p=0.05). In comparing those with PNES on aspirin to PNES controls without (both N=22), there were no differences in any outcomes measured (all p > 0.50).

Conclusions Aspirin use during VEEG resulted led to fewer seizures on day 2 of monitoring in a dose responsive manner. Similar findings were not seen for patients with PNES. Given some diminishement in seizure frequency favoring aspirin use, prospective trials of aspirin therapy may help determine if it helps lower seizure frequencies or epilepsy burden.

Authors/Disclosures
Rachel Godfred PRESENTER	No disclosure on file
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC)	Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with ��ɫ�� that is relevant to AAN interests or activities.
Mihir Parikh	No disclosure on file
	No disclosure on file
Lisa M. Caylor, MD (Swedish Neurosciences)	No disclosure on file
Jehuda P. Sepkuty, MD	No disclosure on file
Michael J. Doherty, MD, FAAN (Swedish Epilepsy Center)	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��